跳至主要内容
临床试验/NCT04107922
NCT04107922已完成3 期

Metabolic Actions of a Supplement of Ilex Paraguariensis, White Mulberry and Chromium Picolinate in Non-diabetic Subjects With Dysglycemia, a Randomized Clinical Trial

University of Pavia2 个研究点 分布在 1 个国家目标入组 148 人开始时间: 2018年10月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
148
试验地点
2
主要终点
Progression of dysglicemia

研究概览

简要总结

The aim will be to evaluate if Glicoset® 1000, a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate, can be effective in improving glycemic status in subject with dysglycemia.

详细描述

The aim will be to evaluate if Glicoset® 1000, a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate, can be effective in improving glycemic status in subject with dysglycemia.

The investigators will enroll patients with impaired fasting plasma glucose (IFG) or impaired glucose tolerance (IGT), not taking hypoglycemic agents (both pharmaceuticals or nutraceutical agents). Patients will be randomized to take placebo or Glicoset® 1000 for 3 months, in a randomized, double-blind, placebo-controlled design. Glicoset® 1000 and placebo will be self-administered once a day, 1 tablet during the breakfast.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with impaired fasting glucose (IFG) or impaired fasting glucose (IGT)
  • Patients not taking hypoglycemic agents (both pharmaceuticals or nutraceutical agents)

排除标准

  • Patients with type 1 or type 2 diabetes mellitus
  • Patients with impaired hepatic function
  • Patient with impaired renal function
  • Patients with gastrointestinal disorders
  • Patients with current or previous evidence of ischemic heart disease, heart failure, or stroke
  • Patients with weight change of > 3 Kg during the preceding 3 months
  • Patients with hystory of malignancy, and significant neurological or psychiatric disturbances, including alcohol or drug abuse.
  • Patients taking (within the previous 3 months) hypoglycemic agents, laxatives, beta-agonists (other than inhalers), cyproheptadine, anti-depressants, antiserotoninergics, phenothiazines, barbiturates, oral corticosteroids, and antipsychotics
  • Women who were pregnant or breastfeeding or of childbearing potential and not taking adequate contraceptive precautions.

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: Placebo (Other)

Glicoset

Active Comparator

Glicoset is a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate

干预措施: Glicoset (Dietary Supplement)

结局指标

主要结局

Progression of dysglicemia

时间窗: 3 months

Oral glucose tolerance test

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Giuseppe Derosa

MD, PhD, FESC

University of Pavia

研究点 (2)

Loading locations...

相似试验